Microvascular Therapeutics Selected by Keiretsu Forum to Present at 2026 Investor Capital Expo in San Francisco

Company Completes Comprehensive Keiretsu Forum Northwest Due Diligence Process and Advances Four Ultrasound-Based Diagnostic and Therapeutic Programs

Tucson, AZ, November 16, 2026 --(PR.com)-- Microvascular Therapeutics, Inc. (MVT), a biotechnology company developing innovative ultrasound contrast agents and ultrasound-mediated therapeutics, announced today that it has been selected by Keiretsu Forum to present at the Investor Capital Expo on November 17, 2026, at the Julia Morgan Ballroom in San Francisco.

MVT has recently completed a comprehensive due diligence process conducted by Keiretsu Forum Northwest, providing prospective investors with a detailed assessment of the company’s technology, development pipeline, intellectual property, and commercial opportunities.

“We are delighted to have been selected to present at the Investor Capital Expo,” said Evan C. Unger, MD, FACR, Chief Executive Officer and Executive Chairman of Microvascular Therapeutics. “The completion of Keiretsu Forum’s due diligence process represents an important step in introducing our technology platform to a broader investor community. We look forward to presenting our clinical progress and the substantial opportunities across our four development programs.”

MVT’s proprietary platform includes:
· CardiSon™: A next-generation ultrasound contrast agent undergoing pivotal clinical evaluation, with a planned NDA submission in 2027.
· Solv™: A novel Phase Shift Microbubble technology intended to improve microvascular perfusion following myocardial infarction.
· NanoBlate™: Ultrasound-activated nanobubbles being developed for targeted, nonthermal treatment of solid tumors.
· Gene Delivery: A platform utilizing ultrasound and engineered microbubbles to facilitate targeted delivery of genetic therapeutics.

The company has received approximately $12 million in non-dilutive funding and is advancing its development programs toward significant clinical and regulatory milestones.

The Investor Capital Expo brings together angel investors, family offices, venture capital representatives, and emerging companies to explore investment and strategic partnership opportunities.

Event Details: November 17, 2026 | 10:00 AM–5:00 PM Pacific
Julia Morgan Ballroom, 465 California Street, San Francisco, CA

About Microvascular Therapeutics, Inc.
Microvascular Therapeutics, Inc. is a biotechnology company developing proprietary ultrasound-based diagnostic and therapeutic technologies. Its pipeline includes CardiSon, Solv, NanoBlate, and a targeted gene delivery platform. The company’s mission is to improve diagnosis and treatment of cardiovascular disease, cancer, and other serious medical conditions through innovative microbubble and nanobubble technologies.

Media and Investor Inquiries
www.mvtpharma.com
Contact
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
ContactContact
Categories

Sign In

New to PR.com?

Get email news alerts fitting your preferences